Special Session
REPORTING CLINICAL TRIALS
Conclusions

Denis Lacombe
EORTC
Brussels, Belgium
Conflict of interest

• None
• The presentations were complementary and to the point of current methodology for complex data interpretation.

• The session has emphasized, through several angles, the need for structured and robust approaches of data reporting.

• There is a growing concern about results reproducibility, and therefore improved transparency and robustness on what we publish is critical at a time when we are embracing a new era of big data and real life approaches. The acceptable level of uncertainty by which clinical research is performed and reported needs to be clearly documented. The learnings, we have made today not only are critical to reinforce robustness of reporting at normal trial completion but have been an eye opener on data reporting risks in specific situations such as early reporting, sub group analysis or when meta-analysis are performed. In such cases, specific methodologies ensure appropriate data reporting and therefore must be mastered by clinical trialists.

• We have a duty to deliver perfectly reliable data which are reported with no flaws so that therapeutic standards do evolve on solid grounds.